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Abstract Mesenchymal stem cells (MSCs) have recently been shown to have not only regener-
ative capabilities but also immunomodulating properties. For this reason, they are
currently under investigation in clinical trials for the treatment of several autoim-
mune systemic disorders. Psoriasis is a systemic immune-mediated disease for which
MSCs could have therapeutic potential. We analysed the existing literature with
regard to MSC-based strategies for the treatment of psoriasis, using the MEDLINE,
Embase, Scopus and Cochrane Library electronic databases from inception to the
date of study. A number of studies confirm the involvement of MSCs in psoriasis
pathogenesis and therefore designate MSCs as an important potential therapeutic
tool in this setting. Preclinical data are mostly based on imiquimod-induced murine
models of psoriasis, and confirm the anti-inflammatory and immunomodulatory
action of MSCs in the setting of psoriasis. Six patients affected by psoriasis were
described in four clinical studies. Despite significant differences in terms of therapeu-
tic protocols and clinical outcomes, the MSC-based regimens were efficacious in
100% of the cases. Despite more data still being needed, MSCs could be a promising
therapy for psoriasis.
Introduction
Psoriasis is a chronic, relapsing inflammatory disease
affecting 2–3% of the population, and is considered to
be a systemic disease rather than one limited to the
skin.1 The treatment varies, depending on disease
severity, from topical agents and phototherapy to con-
ventional immunosuppressant drugs and biologic
agents.2
The pathogenesis of psoriasis has an immunological
basis. A central role is certainly played by T helper
(Th)1 and Th17 lymphocytes and by cytokines such
as tumour necrosis factor (TNF)-a, interleukin (IL)-17
and IL-23.3 However, recent studies have shown that
the prime mover in psoriasis pathogenesis could be
linked to a dysfunction in resident mesenchymal stem
cells (MSCs), resulting in altered polarization of the
immune response.4
Mesenchymal stem cells in psoriasis
MSCs are a subset of pluripotent cells present in tissues
of mesenchymal origin, and are responsible for the
regeneration of these tissues. MSCs are characterized
by specific surface markers and by their ability to
adhere to plastic and to differentiate into adipocytes,
chondrocytes and osteocytes in vitro (Fig. 1).5 MSCs
include many different cell types, with probably the
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most widely studied being the bone-marrow stromal
stem cells (BMSCs). Other MSCs are, for example,
amniotic fluid stem cells, umbilical-cord MSCs
(UCMSCs) and adipose-derived stem cells (ADSCs);
these last are contained in the stromal–vascular frac-
tion (SVF) of adipose tissue.6 MSCs are under study
not only for their regenerative capacity, but also for
their immunomodulating properties, as they seem to
be able to directly modulate cytokine secretion from
lymphocytes.7
A recent work demonstrated that skin MSCs from
patients with psoriasis have low differentiation capac-
ity, high human leucocyte antigen-I expression levels
and low immunoregulatory capability.8 Lymphocyte
inhibition seems to be compromised in psoriatic skin,
mainly because of dermal MSCs, leading to abnormali-
ties in cytokine secretion through circular RNA.9,10
Moreover, MSCs from psoriatic plaques have been
shown to promote keratinocyte proliferation, with sub-
sequent abnormal thickening of the epidermis.11
Several papers have also reported that MSCs seem to
be key players in mediating the pleiotropic effects of
biologic therapies on both keratinocytes and T cells.12
Campanati et al. demonstrated that the effects of TNF-
a inhibitors take place at the level of dermal MSCs,
which probably represent the cells primarily involved
in the ‘psoriatic march’.13,14
In this setting, several authors are investigating the
role of MSCs as a possible therapeutic strategy for the
treatment of psoriasis (Table 1).
Preclinical models
Preclinical data are mostly based on imiquimod (IMQ)-
induced murine models of psoriasis. MSCs demonstrate
efficacy in reduction of disease severity, acanthosis,
inflammatory infiltrate and cytokine production.19,20
In particular, two studies showed the curative poten-
tial of subcutaneous injection of UCMSCs, which seem
to act through direct action both on T lymphocytes
Figure 1 Schematic representation of mesenchymal stem cells (MSCs). MSCs are a subset of pluripotent cells present in tissues of mes-
enchymal origin, such as bone marrow, adipose tissue, placenta, umbilical cord, dermis, skeletal muscle, lungs (upper panel). MSCs are
characterized by the presence of specific surface markers such as CD105, CD73 and CD90 (green box). However, MSCs by definition
lack CD45, CD34, CD14, CD19 and HLAII molecules (red box). Their pluripotency and their regenerative properties are demonstrated
by their ability to differentiate into adipocytes (yellow), chondrocytes (pink) and osteocytes (red) in vitro (lower left panel). MSCs also
interact with both lymphocytes and dendritic cells, therefore modulating cytokine secretion. Created with BioRender.com
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and dendritic cells (DCs), and the study stressed the
importance of an antioxidative milieu for the correct
action of MSCs.15,16 Those data were recently con-
firmed by Chen et al., who demonstrated UCMSC-in-
duced reduction in the production of type I interferon
by plasmacytoid DCs.17 Only one preclinical study has
been performed on ADSCs, which showed that IMQ-in-
duced inflammatory changes are inhibited after intra-
dermal injection of ADSC.18 Human tonsil-derived
MSCs were able to prevent Th17-mediated autoim-
mune response via regulation of the programmed
death-1/programmed death ligand-1 pathway.21
Moreover, Campanati et al. recently confirmed the
in vitro capability of dermal MSCs taken from healthy
controls to revert the proinflammatory cytokine pro-
duction by aberrant MSCs obtained from psoriatic pla-
ques (p-MSCs) and to lower p-MSC proliferation rates
when in coculture.22
Clinical case reports
Our review identified four clinical studies describing a
total of six patients affected by psoriasis treated with
MSC-based regimens (Table 2). The patients generally
had a long-standing history of psoriasis (mean
14.8 years) and most of them were previously pre-
scribed both topical and systemic treatments. All
patients were weaned off any systemic medication for
psoriasis before any MSC-based treatment was admin-
istered. Unlike in haematopoietic-stem-cell transplant
(HSCT), no concomitant drugs are needed before MSC
administration.
In a report from Chen et al.,23 heterologous UCMSCs
were infused intravenously in two patients with psori-
asis. One patient also underwent HSCT for underlying
cancer and not primarily because of psoriasis, there-
fore making it difficult to draw conclusions on MSC
effectiveness in that particular case.23
De Jesus et al.24 described two patients with psoria-
sis who were infused with autologous ADSCs, which
had been obtained through centrifugation and enzy-
matic digestion of lipoaspirates and subsequent plat-
ing. While one patient received two doses of ADSCs,
the other required three doses. Both patients experi-
enced significant cutaneous improvement of but did
not reach complete clearance, and therefore required
additional therapies. One of the patients also had pso-
riatic arthritis, which did not respond to the ADSC-
based treatment.
Comella et al.25 recently published a report on
successful intravenous injection of autologous SVF in
a patient affected by psoriasis. Fresh SVF from
lipoaspirate was resuspended in normal saline solu-
tion for administration through a 23G butterfly nee-
dle. The patient experienced complete clearance of
the disease, with no recurrences during the follow-
up period.
Seetharaman et al.26 also described the efficacy of
topical application of ADSC-conditioned medium (CM)
in a localized form of scalp psoriasis. ADSCs from a
healthy volunteer were plated and the MSC-CM was
collected after 72 h of incubation, centrifuged, filtered,
concentrated by ultrafiltration and stored at 20 °C
until use. MSC-CM was applied directly to the affected
Table 1 Study characteristics (results of our review). Summary of the results obtained from our search: name of the first author
(authors are listed in alphabetical order), year and type of publication, type of study and type of mesenchymal stem cell used.
Study Author Publication year Publication type Study type MSC type
1 Campanati et al.22 2018 Original article Preclinical dMSC
2 Chen et al.23 2016 Letter Clinical UCMSC
3 Chen et al.17 2019 Original article Preclinical UCMSC
4 Comella et al.25 2018 Case report Clinical SVF (ADSC)
5 Imai et al.20 2019 Letter Preclinical AmnMSC
6 De Jesus et al.24 2016 Case report Clinical ADSC
7 Kim et al.21 2018 Original article Preclinical TMSC
8 Kim et al.19 2019 Original article Preclinical EMSC
9 Lee et al.15 2017 Original article Preclinical UCMSC
10 Rokunohe et al.18 2016 Letter Preclinical ADSC
11 Owczarczyk-Saczonek et al.28 2017 Review Preclinical, clinical BMSC, UCMSC
12 Sah et al.16 2016 Original article Preclinical UCMSC
13 Seetharaman et al.26 2019 Case report Clinical ADSC
ADSC, adipose-derived stem cell; AmnMSC, amniotic fluid stem cells; BMSC, bone-marrow stromal stem cell; dMSC, dermal mesenchy-
mal stem cell; EMSC, embryonic stem cell-derived mesenchymal stem cell; MSC, mesenchymal stem cell; SVF, stromal–vascular fraction;
TMSC, tonsil-derived mesenchymal stem cell; UCMSC, umbilical cord mesenchymal stem cell.
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area on a daily basis for 30 days, with significant clin-
ical improvement and stable results.
In all four studies, the efficacy of the MSC-based reg-
imen was 100%. Only two of the six patients relapsed,
but the relapses after MSC-based treatment regimens
were generally milder forms of psoriasis and responded
to systemic therapy. No serious adverse events were
registered. TBC reactivation and infections were seen
only in patients receiving concomitant immunosup-
pression or biologic therapies.
Discussion
MSCs are currently used in clinical trials for a great
variety of diseases, with a special focus on autoim-
mune disorders.27 The feasibility of MSC transplanta-
tion is highly dependent on the type of cell used: for
example, while BMSC isolation requires a specialist
team, ADSCs are easily accessible and therefore a
much simpler treatment.
Previous studies have already confirmed the involve-
ment of MSCs in the pathogenesis of psoriasis and
therefore designated MSCs as important potential ther-
apeutic targets.28 It is unclear if genetic polymor-
phisms responsible for genetic predisposition to
psoriasis could represent a primary cause of MSC dys-
function. It remains undetermined whether the local
dysfunction of MSC in psoriatic plaques is only a local-
ized phenomenon or if it reflects a failure in MSC func-
tioning in general. Moreover, the published studies
display wide variation in terms of types of cell used
and the methods of administration, therefore making
it impossible at present to define a standardized proto-
col. Those are central points for future studies aimed
at determining the feasibility and efficacy of autolo-
gous MSC transplantation.
Despite many promising reasons for the use of MSCs
in psoriasis, it should also be noted that the direct
regenerative potential of these cells may not be as
effective as previously expected. There are also poten-
tial risks associated with MSC therapy, including graft-
versus-host disease, neoplastic proliferation, localized
cutaneous reactions and lack of efficacy. The likeli-
hood of those adverse events varies according to the
type of cell used and the method of administration.
Assessment of the potential risks and benefits is essen-
tial before MSC-based therapeutic regimens can be
considered a treatment of choice for psoriasis.29,30
Conclusion
We analysed four studies on six patients that used
MSC therapy for psoriasis. Although all six patients
benefited from the treatment, there were relapses. MSC
treatment is also not without risk. Further data are
needed to determine whether MSC-based strategies
could be included in official guidelines for the treat-
ment of psoriasis.
Learning points
• MSCs do not only display regenerative capabili-
ties but also have immunomodulating properties.
• Th1 and Th17 lymphocyte inhibition is com-
promised in psoriatic skin, mainly because of
MSCs in psoriatic lesions affecting the skin
microenvironment.
• A central role is played by MSCs in the response
to biologic therapies; MSCs in fact seem to be key
players in mediating the pleiotropic effects of those
drugs on both keratinocytes and T cells.
• Preclinical data were mostly based on IMQ-in-
duced murine models of psoriasis, and confirmed
the anti-inflammatory and immunomodulatory
action of MSCs in the setting of psoriasis.
• Several studies have demonstrated the efficacy
of MSC administration both in patients with pso-
riasis and in animal models of psoriasis.
• To date, only six patients affected by psoriasis
have successfully been treated with MSC-based
regimens
• In addition, the wide variation in terms of types
of cell and methods of administration mean that
there are no standardized protocols.
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CPD questions
Question 1
What are the main types of cells involved in the
pathogenesis of psoriasis?
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(a) T helper (Th)1 and Th2.
(b) Th3 and Th17.
(c) Regulatory T cells and Th2.
(d) Th1 and Th17.
(e) B cells and Th17.
Question 2
Which of the following are possible treatments for pso-
riasis?
(a) Acitretin, ciclosporin, amoxicillin.
(b) Methotrexate, imiquimod, adalimumab.
(c) Secukinumab, aciclovir, ustekinumab.
(d) Topical clobetasol, topical pimecrolimus, inflix-
imab.
(e) Topical clobetasol, methotrexate, adalimumab.
Question 3
Which of the following statements about mesenchymal
stem cells (MSCs) is correct?
(a) MSCs are directly responsible for interleukin-17
and tumour necrosis factor-a secretion.
(b) MSCs are directly responsible for superinfection of
psoriatic plaques by Staphyloccus aureus.
(c) MSCs do not show any particular alteration in
psoriatic plaques.
(d) MSCs are directly linked to pathological T helper
(Th)1–Th17/Th2 imbalance and may interact
directly with keratinocytes.
(e) MSCs are responsible for acantholysis and for
plasma cell recruitment in psoriatic plaques.
Question 4
Mesenchymal stem cells are a potentially powerful
instrument for the treatment of psoriasis because of
what properties?
(a) Their regenerative properties.
(b) Their proinflammatory properties.
(c) Their antibacterial properties.
(d) Their immunomodulating properties.
(e) Their antitumoral properties.
Question 5
The current available clinical data regarding the use
of mesenchymal stem cells as a treatment for psoriasis
has demonstrated which of the following?
(a) Lack of efficacy.
(b) Efficacy hampered by serious adverse events such
as patient death and liver failure.
(c) Efficacy but with relapse rates of > 50%.
(d) Efficacy, but with one-third of the patients relaps-
ing after treatment.
(e) Only partial efficacy, with no adverse events.
Instructions for answering questions
This learning activity is freely available online at
http://www.wileyhealthlearning.com/ced
Users are encouraged to
• Read the article in print or online, paying particular
attention to the learning points and any author
conflict of interest disclosures
• Reflect on the article
• Register or login online at http://www.wileyhealth
learning.com/ced and answer the CPD questions
• Complete the required evaluation component of the
activity
Once the test is passed, you will receive a certificate
and the learning activity can be added to your RCP
CPD diary as a self-certified entry.
This activity will be available for CPD credit for
2 years following its publication date. At that time, it
will be reviewed and potentially updated and extended
for an additional period.
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